Head to Head Contrast: MDxHealth (NASDAQ:MDXH) and Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics (NASDAQ:TRDA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

Entrada Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Entrada Therapeutics and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	2	4	0	2.43
MDxHealth	1	4	1	0	2.00

Entrada Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 238.10%. MDxHealth has a consensus price target of $1.33, indicating a potential upside of 857.17%. Given MDxHealth’s higher possible upside, analysts clearly believe MDxHealth is more favorable than Entrada Therapeutics.

Profitability

This table compares Entrada Therapeutics and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-4,057.98%	-64.00%	-50.49%
MDxHealth	-33.46%	N/A	-24.25%

Valuation & Earnings

This table compares Entrada Therapeutics and MDxHealth”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42 million	8.09	-$143.75 million	($3.84)	-1.37
MDxHealth	$107.88 million	0.06	-$33.52 million	($0.72)	-0.19

MDxHealth has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Summary

MDxHealth beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments. Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.

About MDxHealth

MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning. MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.